Understanding Cemdisiran's Mechanism of Action in Myasthenia Gravis

02 Nov 2026 0 comments

Ali Habib, MD, neuromuscular specialist at UCI Health, explains the rationale behind cemdisiran's liver-directed RNA interference approach and how it differs from established C5 inhibition strategies in generalized myasthenia gravis.

Source: NeurologyLive Published 02 Nov 2026 Imported 02 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment